ライフサイエンスコーパス: idiopathic pulmonary arterial hypertension

1 apacity and quality of life in patients with idiopathic pulmonary arterial hypertension.

2 n the changing demographics of patients with idiopathic pulmonary arterial hypertension.

3 on of a novel gene, KCNK3, with familial and idiopathic pulmonary arterial hypertension.

4 arterial hypertension and 230 patients with idiopathic pulmonary arterial hypertension.

5 ptions for treatment of medically refractory idiopathic pulmonary arterial hypertension.

6 pulmonary vascular lesions of patients with idiopathic pulmonary arterial hypertension.

7 ptosis and the loss of small vessels seen in idiopathic pulmonary arterial hypertension.

8 P) provide such information in patients with idiopathic pulmonary arterial hypertension.

9 nguishable from those found in patients with idiopathic pulmonary arterial hypertension.

10 current treatment options for children with idiopathic pulmonary arterial hypertension.

11 of endothelial cells in plexiform lesions in idiopathic pulmonary arterial hypertension.

12 ence and point prevalence of 0.7 and 4.4 for idiopathic pulmonary arterial hypertension and 2.2 and 1

13 thin the pulmonary adventitia of humans with idiopathic pulmonary arterial hypertension and animals w

14 without anemia is prevalent in patients with idiopathic pulmonary arterial hypertension and associate

15 ein levels were elevated in lungs from human idiopathic pulmonary arterial hypertension and in lungs

16 B, MANTIS was downregulated in patients with idiopathic pulmonary arterial hypertension and in rats t

17 derived endothelial cells from patients with idiopathic pulmonary arterial hypertension and in the pu

18 Adults diagnosed with idiopathic pulmonary arterial hypertension and listed fo

19 d retinoid levels in plasma of patients with idiopathic pulmonary arterial hypertension and the effec

20 the walls of small intrapulmonary vessels in idiopathic pulmonary arterial hypertension and the rare

21 survival in transplantation candidates with idiopathic pulmonary arterial hypertension, as is being

22 derived endothelial cells from patients with idiopathic pulmonary arterial hypertension attenuated th

23 and in lungs of patients with emphysema and idiopathic pulmonary arterial hypertension comparably ex

24 ervation that lung tissue from patients with idiopathic pulmonary arterial hypertension demonstrated

25 Survival for children with idiopathic pulmonary arterial hypertension has significa

26 rrent diagnostic and treatment strategies of idiopathic pulmonary arterial hypertension in children h

27 Treatment for idiopathic pulmonary arterial hypertension in children i

28 olic volume is a strong prognostic marker in idiopathic pulmonary arterial hypertension, independent

29 Vascular remodeling in idiopathic pulmonary arterial hypertension (IPAH) involv

30 Idiopathic pulmonary arterial hypertension (IPAH) is a c

31 Idiopathic pulmonary arterial hypertension (IPAH) is a l

32 Idiopathic pulmonary arterial hypertension (IPAH) is pat

33 Idiopathic pulmonary arterial hypertension (IPAH) is usu

34 ted an altered hyaluronan (HA) metabolism in idiopathic pulmonary arterial hypertension (IPAH) lung t

35 AR-2 and tryptase expression in the lungs of idiopathic pulmonary arterial hypertension (IPAH) patien

36 Idiopathic pulmonary arterial hypertension (IPAH) result

37 opathic pulmonary fibrosis (IPF) and 38 with idiopathic pulmonary arterial hypertension (IPAH), the l

38 lays an important role in the development of idiopathic pulmonary arterial hypertension (IPAH), where

39 (SScPAH) has a worse prognosis compared with idiopathic pulmonary arterial hypertension (IPAH), with

40 ation has been recommended for patients with idiopathic pulmonary arterial hypertension (IPAH).

41 nifedipine, have been used for treatment of idiopathic pulmonary arterial hypertension (IPAH).

42 egmental pulmonary arteries in children with idiopathic pulmonary arterial hypertension (IPAH).

43 ll as in arteries of patients suffering from idiopathic pulmonary arterial hypertension (IPAH).

44 est) and clinical worsening in patients with idiopathic pulmonary arterial hypertension (IPAH).

45 pulmonary fibrosis (IPF), and patients with idiopathic pulmonary arterial hypertension (IPAH).

46 elevance of iron deficiency in patients with idiopathic pulmonary arterial hypertension (IPAH).

47 levated vascular resistance in patients with idiopathic pulmonary arterial hypertension (IPAH).

48 pacitance predicts survival in patients with idiopathic pulmonary arterial hypertension (IPAH).

49 ait similar to that of certain patients with idiopathic pulmonary arterial hypertension (IPAH).

50 hemodynamics, and survival in patients with idiopathic pulmonary arterial hypertension (IPAH).

51 r blocker, has been used clinically to treat idiopathic pulmonary arterial hypertension (IPAH).

52 lmonary vascular resistance in patients with idiopathic pulmonary arterial hypertension (IPAH).

53 Long-term anticoagulation is recommended in idiopathic pulmonary arterial hypertension (IPAH).

54 We show that cultured ECs from patients with idiopathic pulmonary arterial hypertension (IPAH-ECs) ha

55 ally classified as pre-capillary (as seen in idiopathic pulmonary arterial hypertension [IPAH]) or po

56 nd transplantation outcomes in patients with idiopathic pulmonary arterial hypertension is poorly des

57 Although several studies have focused on idiopathic pulmonary arterial hypertension, less is know

58 The majority had idiopathic pulmonary arterial hypertension (n=30); the r

59 Idiopathic pulmonary arterial hypertension (PAH [IPAH])

60 Heritable and idiopathic pulmonary arterial hypertension (PAH) are phe

61 othelial cells (PAECs) from patients who had idiopathic pulmonary arterial hypertension (PAH) in comp

62 nt in the vascular lesions of PH, whether in idiopathic pulmonary arterial hypertension (PAH) or PAH

63 mponents of pulmonary vascular remodeling in idiopathic pulmonary arterial hypertension (PAH).

64 bsent in pulmonary arteries of patients with idiopathic pulmonary arterial hypertension (PAH).

65 ent in pulmonary arteries from patients with idiopathic pulmonary arterial hypertension (PAH).

66 aph-mass spectrometer technique in plasma of idiopathic pulmonary arterial hypertension patients and

67 Idiopathic pulmonary arterial hypertension patients have

68 In lung samples from idiopathic pulmonary arterial hypertension patients, pax

69 andidates for treatments previously used for idiopathic pulmonary arterial hypertension patients.

70 th severe hypoxia-induced PH and humans with idiopathic pulmonary arterial hypertension (PH-Fibs) dis

71 Although there is no cure for idiopathic pulmonary arterial hypertension, recent medic

72 Idiopathic pulmonary arterial hypertension subgroup anal

73 ns in the BMP type II receptor (BMPRII) with idiopathic pulmonary arterial hypertension suggests an i

74 Consecutive patients with idiopathic pulmonary arterial hypertension underwent car

75 well as increased survival in patients with idiopathic pulmonary arterial hypertension using current

76 l cells cultured from lungs of patients with idiopathic pulmonary arterial hypertension versus contro

77 ist mortality has decreased in patients with idiopathic pulmonary arterial hypertension wait-listed f

78 hildren diagnosed between 1982 and 1995 with idiopathic pulmonary arterial hypertension was followed

79 Until recently, the diagnosis of idiopathic pulmonary arterial hypertension was virtually

80 seven control subjects and six patients with idiopathic pulmonary arterial hypertension were analyzed

81 A total of 80 patients with idiopathic pulmonary arterial hypertension were identifi

82 Additional patients with familial or idiopathic pulmonary arterial hypertension were screened

83 patients with HRPH, but not in patients with idiopathic pulmonary arterial hypertension, were also Ne

84 e (CMR) is useful for risk stratification in idiopathic pulmonary arterial hypertension, whereas it h

85 ovascular magnetic resonance measurements in idiopathic pulmonary arterial hypertension, with no stud